Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact
Entreprenorsstraket 10
GoCo House
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,311.90 | 125.80 | 1.37% |
| CAC 40 | 8,631.62 | 17.80 | 0.21% |
| DAX 40 | 26,185.07 | 183.76 | 0.71% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,903.93 | 46.23 | 0.43% |
| HKSE | 25,852.92 | 156.48 | -0.60% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,957.53 | 202.63 | 0.32% |
| NZX 50 Index | 13,903.46 | 128.53 | 0.93% |
| S&P 500 | 7,600.50 | 110.78 | 1.48% |
| S&P/ASX 200 | 9,145.80 | 122.80 | 1.36% |
| SSE Composite Index | 3,822.28 | 12.62 | 0.33% |